Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, November 11, 2026, at 2:30 PM ET. To register, click here.

The event will feature expert oncologists Eileen M. O’Reilly, MD, FASCO and Kevin C. Soares, MD, both of Memorial Sloan Kettering Cancer Center (”MSKCC”), who will join the Company’s management to discuss: * The unmet need and current treatment landscape for metastatic pancreatic ductal adenocarcinoma (“PDAC”) * Camupepimut (ELI-002 7P), Elicio’s investigational Amphiphile (“AMP”)-powered immunotherapy targeting common KRAS mutations * Key Phase 2 findings informing camupepimut’s late-stage development strategy * Opportunities to expand camupepimut into neoadjuvant PDAC, including the design and progress of the ongoing MSKCC-led Phase 1 trial funded by The Lustgarten Foundation and Break Through Cancer A live question and answer session will follow the formal presentations.